Author(s)

Grazia Artioli, Giuseppe Azzarello, Fabrizio Meggiolaro, Jacopo Wabersich, Lucia Borgato, Mario Bari

Department of Medical Science, Oncology-Haematology, Mirano, Italy.
Department of Obstetrics and Gynecology, Mirano, Italy.
Department of Surgery, Mirano, Italy.

Background: Metastatic breast cancer in BRCA 2 patients is lacking of target therapy studies. Case: We present a case of a 34-year-old woman affected by a recurrent metastatic breast cancer after 5 years treated with weekly nab-paclitaxel and three weekly Cisplatin obtaining a radiological complete response with 6 cycles. Conclusion: It is important to emphasize that patients with a molecular disorder who selected for “target” chemotherapy can obtain optimal response rate. Exploiting the mechanism of action of DNA damage in our favor, using cisplatin for example and basing on literature show the efficacy of using taxane in BRCA 2 patients, obtaining a very high response rate.

BRCA 2; Breast Cancer; DNA; Cisplatin; Taxane

Artioli, G. , Azzarello, G. , Meggiolaro, F. , Wabersich, J. , Borgato, L. and Bari, M. (2013) Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer. Advances in Breast Cancer Research, 2, 56-59. doi: 10.4236/abcr.2013.23010.